The p53 pathway as a target in cancer therapeutics: obstacles and promise

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mutations in the p53 tumor suppressor gene are prevalent in human cancers, driving tumor initiation and progression.
• Restoring wild-type p53 function has demonstrated potent tumor elimination capabilities.
• p53 pathway activators are emerging as promising anticancer drug candidates.

Purpose of the Study:

• To review the current landscape of p53 pathway activators in cancer therapy.
• To address the challenges and toxicities associated with p53-activating compounds.
• To propose optimized screening strategies for identifying novel p53-targeting molecules.

Main Methods:

• Literature review of studies on p53 pathway activators and their clinical translation.
• Analysis of preclinical and clinical data regarding the efficacy and toxicity of p53 activators.
• Discussion of screening methodologies for drug discovery.

Main Results:

• Several p53 pathway-activating compounds have advanced to clinical trials for various cancers.
• Some p53 activators exhibit dose-limiting toxicities in normal tissues, impacting therapeutic potential.
• There is a need for improved screening methods to identify safer and more effective p53 activators.

Conclusions:

• p53 reactivation holds significant promise for cancer treatment, with active clinical development.
• Managing toxic side effects is crucial for the successful application of p53 activators.
• Enhanced and expanded screening strategies are essential to discover next-generation p53-targeting anticancer agents.